Low-dose paclitaxel modulates the cross talk between the JNK and Smad signaling in primary biliary fibroblasts

Jiamei Lu1, Liang Yu2, Jianhua Shi2*©

SUMMARY

OBJECTIVE: The objective of this study was to explore the molecular mechanism underlying the occurrence of benign bile duct stricture and the target of low-dose paclitaxel in the prevention of benign bile duct stricture.

METHODS: Under the stimulation of transforming growth factor beta 1, the expression of collagen type I and connective tissue growth factor were detected on isolated primary fibroblasts. The phosphorylation levels of JNK and Smad2L were detected using Western blot. The effect of low-dose paclitaxel on the transforming growth factor beta 1-induced inhibition of type I collagen and connective tissue growth factor expression and JNK and Smad2L phosphorylation was also observed.

RESULTS: Transforming growth factor beta 1 induced the secretion of type I collagen and connective tissue growth factor as well as JNK phosphorylation in biliary fibroblasts. The JNK inhibitor or siRNA-Smad2 inhibited the transforming growth factor beta 1-induced secretion of type I collagen and connective tissue growth factor. Low-dose paclitaxel inhibited the expression of type I collagen induced by transforming growth factor beta 1 and may inhibit the secretion of collagen in biliary fibroblasts.

CONCLUSION: The activation of JNK/Smad2L induced by transforming growth factor beta 1 is involved in the occurrence of benign bile duct stricture that is mediated by the overexpression of type I collagen and connective tissue growth factor, and low-dose paclitaxel may inhibit the phosphorylation of JNK/Smad2L.

KEYWORDS: Bile duct. Fibroblasts. JNK. Smad. Paclitaxel.

INTRODUCTION

Anastomotic stricture of the bile duct is one of the main complications after liver transplantation, and the incidence rate is as high as 24.9%1. The incidence of biliary stricture after living-donor liver transplantation in children is as high as 10–35%2. Bile duct stricture severely affects the life and treatment of patients. Therefore, in order to effectively prevent benign bile duct stricture, it is necessary to explore the molecular mechanism underlying the occurrence of benign bile duct stricture.

Recent studies have found that low-dose paclitaxel can prevent tissue fibrosis3–5, and clinically, paclitaxel coating has been used to prevent the occurrence of luminal narrowing of blood vessels6. Preliminary animal studies of this subject showed that low-dose paclitaxel-coated stents can inhibit the activation of biliary-enteric anastomosis fibroblasts and the secretion of collagen through slow topical administration, but the specific molecular mechanism is still unclear7. In this study, we aimed to explore the molecular mechanism underlying the occurrence of benign bile duct stricture. At the same time, the effect of low-dose paclitaxel on the inhibition of type I collagen and connective tissue growth factor (CTGF) secretion investigated in relation to the molecular mechanisms was also obtained.

METHODS

Isolation, culture, and identification of primary biliary fibroblasts

The isolation, culture, and identification of primary biliary fibroblasts were performed according to the earlier reported procedure from Wistar rats8. The following experiments were performed using the fifth generation cells, and the cells were starved with 10 mL/L fetal calf serum for 12 h before any interventions. SP600125 (Calbiochem, USA) inhibits JNK phosphorylation. Paclitaxel was purchased from Sigma, and transforming growth factor beta 1 (TGF-β1) was purchased from Peprotech. The experiment was approved by the Animal Ethical Board for Biomedical Experiments of The First Affiliated Hospital of Xi’an Jiaotong University.

1The Second Affiliated Hospital of Xi’an Jiaotong University, Department of Nephrology – Xi’an, China.
2The First Affiliated Hospital of Xi’an Jiaotong University, Department of Hepatobiliary Surgery – Xi’an, China.
*Corresponding author: shi_jian_1981@sina.com

Conflicts of interest: the authors declare there is no conflicts of interest. Funding: The study was supported by the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province for funding MRTF-A mediates the epigenetic mechanism of renal tubular epithelial cell transdifferentiation induced by high glucose (81700605) and design and optimization of the surface treatment of a new type of biliary degradable stent (2021JM-269), respectively.

Received on October 08, 2021. Accepted on October 09, 2021.
siRNA transient transfection of siRNA into cells
Transfection was carried out using Lipofectamine 2000 in accordance with Invitrogen's manufacturer protocol. Western blotting was performed for 48 h after transfection to determine the inhibitory effect on protein expression.

Enzyme-linked immunosorbent assay test
Following centrifugation at 1,000 r/min for 5 min at 4°C, the supernatant of medium was collected and stored in a refrigerator at -20°C. The type I collagen enzyme-linked immunosorbent assay detection kit (MyBioSource, San Diego, CA, USA) was used to detect the corresponding protein expression level in accordance with the manufacturer's instructions.

Western blotting for the detection of protein levels
The proteins were separated using SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane. The membrane was blocked with 0.1% BSA in PBS for 1 h at room temperature and then incubated with the primary antibodies in PBST overnight at 4°C. The membrane was incubated with a goat anti-rabbit secondary antibody (1:2,000) for 1 h at room temperature. Scion NIH image analysis software was used to detect the intensity of the protein bands on Western blot in order to determine the expression level of the target protein.

Statistical analysis
The experimental results are expressed as mean±standard deviation. One-way analysis of variance was used to compare multiple groups of data, while the comparison between the two groups was performed by LSD test using SPSS version 17.0 software. p<0.05 was regarded as statistically significant, and p<0.01 was regarded as the difference of high statistical significance.

RESULTS
Transforming growth factor beta 1 induces collagen secretion in biliary fibroblasts
According to Table 1 and Figure 1A, TGF-β1 induced the secretion of type I collagen in biliary fibroblasts in a dose-dependent manner, and 10 ng/mL TGF-β1 increased the level of type I collagen secreted by 2.07 times compared with the control group (p<0.01).

Transforming growth factor beta 1 induces the expression of connective tissue growth factor in biliary fibroblasts in a dose-dependent manner
As shown in Figure 1B, TGF-β1 induced the CTGF expression in a dose-dependent manner, and we found that 10 ng/mL TGF-β1 increased the CTGF expression by 3.28 times as compared to the control group (p<0.01).

Transforming growth factor beta 1 induces phosphorylation of JNK in biliary fibroblasts in a dose-dependent manner
As shown in Figure 1C, 3 ng/mL TGF-β1 increased the phosphorylation level of JNK as compared to the control group (p<0.05), whereas 5 ng/mL TGF-β1 increased the phosphorylation level of JNK by 3.85 times compared with the control group (p<0.01).

Transforming growth factor beta 1-induced phosphorylation of JNK mediates the activation of Smad2L
In comparison with the control group, the phosphorylation of Smad2L was induced in the TGF-β1 group (p<0.05). In contrast, compared with the TGF-β1 group, the JNK inhibitor SP600125 inhibited the phosphorylation of Smad2L mediated by TGF-β1 (p<0.05; Figure 1D).

Selection of Smad2 gene-specific siRNA for biliary fibroblasts via Smad2 siRNA interference screening
As shown in Figure 1E, the Western blot following 48 h post-transfection indicates that Smad2 siRNA-3 had a significant inhibitory effect on the negative control group and the blank control group (p<0.01), while Smad2 siRNA-1 and -2 had no obvious inhibitory effect. Therefore, we chose Smad2 siRNA 3 for follow-up experiments.

Table 1. Transforming growth factor beta 1 induces collagen secretion in biliary fibroblasts.

| Concentration of Transforming growth factor beta 1 (ng/mL) | 0       | 1       | 3       | 10      |
|----------------------------------------------------------|---------|---------|---------|---------|
| Concentration of collagen (ng/mL)                        | 2.37±0.76| 2.51±0.50| 3.35±1.05| 4.90±1.06*|

*The difference is statistically significant (p<0.01) in comparison with the control group.
Transforming growth factor beta 1 activates the JNK/Smad2L signaling pathway and mediates the secretion of connective tissue growth factor

Compared with the control group, the expression level of CTGF in the TGF-β1 group was enhanced (p<0.01). The JNK inhibitor SP600125 inhibited the expression level of CTGF that was mediated by TGF-β1 as compared with the TGF-β1 group. In the Smad2 siRNA group, TGF-β1-mediated CTGF expression was also inhibited. Compared with the JNK inhibitor group and the Smad2 siRNA group, no significant difference in the expression level of CTGF mediated by TGF-β1 was observed. Thus, it might be suggested that TGF-β1 mediates the expression of CTGF by activating the JNK/Smad2L signaling pathway (Figure 1F).

Transforming growth factor beta 1 induces the phosphorylation of JNK and Smad2L and mediates the expression of type I collagen

Figure 2A shows that compared with the control group, the expression level of type I collagen of the TGF-β1 group was increased (p<0.01). The JNK inhibitor SP600125 inhibited the expression level of type I collagen mediated by TGF-β1. In the Smad2 siRNA group, the expression level of type I collagen mediated by TGF-β1 was also inhibited. Therefore, these
findings suggest that TGF-β1 mediates the expression of type I collagen by activating the JNK/Smad2L signaling pathway.

**Paclitaxel inhibits transforming growth factor beta 1-mediated secretion of type I collagen in biliary fibroblasts in a dose-dependent manner**

As shown in Figure 2B, 10 ng/mL TGF-β1 significantly increased the secretion of type I collagen in biliary fibroblasts as compared with the control group. Paclitaxel dose-dependently inhibited the TGF-β1-mediated secretion of type I collagen in biliary fibroblasts. Particularly, 20 nmol/L paclitaxel significantly reduced the secretion of type I collagen in biliary fibroblasts compared with the TGF-β1 group, suggesting that 20 nmol/L paclitaxel has a significant inhibitory effect on TGF-β1-induced type I collagen secretion in biliary fibroblasts. In the absence of TGF-β1 stimulation, paclitaxel has no significant effect on type I collagen of biliary fibroblasts (compared with the blank control group, p>0.05). Therefore, 20 nmol/L paclitaxel was chosen for follow-up experimental research.
Effect of paclitaxel on JNK phosphorylation induced by transforming growth factor beta 1

The results in Figure 2C indicate that paclitaxel can significantly inhibit the level of JNK phosphorylation induced by TGF-β1 (p<0.05, compared with the TGF-β1 group). However, its effect was not statistically different compared with the JNK inhibitor group (p>0.05).

Effect of paclitaxel on transforming growth factor beta 1-mediated phosphorylation of Smad2L

In order to explore whether paclitaxel can inhibit the phosphorylation of Smad2L induced by TGF-β1, the results in Figure 2D indicate that paclitaxel can significantly inhibit the phosphorylation of Smad2L induced by TGF-β1 (p<0.05, compared with the TGF-β1 group). Nevertheless, there is no statistical difference in its effect when compared with the JNK inhibitor group or siRNA group (p>0.05).

Paclitaxel inhibits the transforming growth factor beta 1-mediated expression of connective tissue growth factor in biliary fibroblasts

To examine whether paclitaxel can inhibit TGF-β1-induced expression of CTGF, the results in Figure 2E indicate that paclitaxel can significantly inhibit the TGF-β1-induced secretion of CTGF compared with the TGF-β1 group, and its effect is similar to that in the TGF-β1 group. Nevertheless, there was no statistical difference when compared with the JNK inhibitor group or the siRNA group (p>0.05), indicating that paclitaxel inhibits CTGF secretion possibly via the suppression of the phosphorylation of JNK and Smad2L.

DISCUSSION

A growing body of evidence suggests that non-Smad pathways are involved in the transduction of TGF-β signals. These non-Smad pathways can be directly mediated by TGF-β or can involve in the regulation of TGF-β/Smad signal transduction, thereby bestowing TGF-β with multiple biological functions. Recently, Lessard et al. found that JNK can adjust skeletal muscle remodeling through Smad2. Shapira et al. reported that increased phosphorylation of JNK can increase the translation and activation of Smad2/3 induced by TGF-β. Smads protein is composed of conserved MH1, MH2, and intermediate linking regions and a central mediator of TGF-β signal transduction. TGF-β type I receptor (TβRI) phosphorylates the COOH-terminal serine residues of Smads protein activated by membrane receptors, and the intermediate linking region can be phosphorylated by Ras-related kinases, such as ERK, JNK, P38, and CDK4.

TGF-β1 not only directly mediates the phosphorylation of the COOH-terminal serine residues of Smads by activating the TβRI but also promotes the activation of Ras-related kinases through TGF-β activated kinase 1 and mediates the phosphorylation of Smads protein linking region to coordinate TGF-β1 signal transduction. The TGF-β1-mediated Ras-related kinase-dependent Smad2/3 intermediate linking region promotes not only cell proliferation but also tissue fibrosis. Abe et al. found that ERK1/2 contributed to the increase of the collagen synthesis mediated by TGF-β1 in cardiac fibroblasts, which was accompanied by phosphorylation of the intermediate linking region of Smad2, while the loss of ERK significantly down-regulated the expression of collagen. In this study, TGF-β1 induced the expression of CTGF and type I collagen in a dose-dependent manner, accompanied by increased phosphorylation of JNK and Smad2L, and inhibition of phosphorylation of JNK or Smad2L could reduce the expression of CTGF and type I collagen. JNK inhibitors can also inhibit the phosphorylation of Smad2L induced by TGF-β1, suggesting that the TGF-β1-induced expression of CTGF and type I collagen in biliary fibroblasts is mediated by the JNK/Smad2L pathway. Hence, TGF-β1/JNK/Smad2L is involved in the occurrence of benign bile duct stricture.

Recent studies suggest that low-dose paclitaxel (10–50 nM) is able to prevent tissue fibrosis by regulating the TGF-β1/Smads signaling pathway and inhibiting the phosphorylation of Smad2/3 to reduce the deposition of collagen. The results of this study suggest that low-dose paclitaxel inhibits the TGF-β1-induced secretion of collagen in a dose-dependent manner, accompanied by the inhibition on phosphorylation of JNK and Smad2L. Therefore, we found that low-dose paclitaxel-induced inhibitory effect on the secretion of collagen may be achieved by inhibiting the phosphorylation of JNK and Smad2L, and low-dose paclitaxel may regulate the TGF-β1/Smads signaling pathway through JNK to downregulate collagen secretion in human biliary fibroblasts.

CONCLUSION

Our present study demonstrated that activation of JNK/Smad2L induced by TGF-β1 is involved in the occurrence of benign bile duct stricture that is mediated by the overexpression of type I collagen and CTGF, and low-dose paclitaxel may inhibit the phosphorylation of JNK/Smad2L.

AUTHORS’ CONTRIBUTIONS

JL, LY: Performed the study. Analyzed the data. Wrote the initial draft of this manuscript. JS: Conceptualized and supervised the study. Approved the final version of this manuscript.
REFERENCES

1. Jarlot-Gas C, Muscari F, Mokrane FZ, Del Bello A, Culetto A, Buscail E, et al. Management of anastomotic biliary stricture after liver transplantation and impact on survival. HPB (Oxford). 2021;23(8):1259-68. https://doi.org/10.1016/j.hpb.2020.12.008

2. Yoshizumi T, Harada N, Mori M. Biliary stricture: the Achilles heel of pediatric living donor liver transplantation. Transplantation. 2019;103(9):1758-9. https://doi.org/10.1097/TP.0000000000002573

3. Wang M, Chen L, Huang W, Jin M, Wang Q, Gao Z, et al. Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. Int J Nanomed. 2019;14:1385-400. https://doi.org/10.2147/IJN.S195375

4. Luan J, Zhang Z, Sheng W, Chen Y, Yang X, Chen X, et al. Thermogel loaded with low-dose paclitaxel as a facile coating to alleviate periprosthetic fibrous capsule formation. ACS Appl Mater Interfaces. 2018;10(36):30235-46. https://doi.org/10.1021/acsami.8b13548

5. Sharawy MH, El-Awady MS, Makled MN. Protective effects of paclitaxel on thioacetamide-induced liver fibrosis in a rat model. J Biochem Mol Toxicol. 2021;35(5):e22745. https://doi.org/10.1002/jbt.22745

6. Krishnan P, Purushothaman KR, Purushothaman M, Tarricone A, Chen S, Singla S, et al. Histological features of restenosis associated with paclitaxel drug-coated balloon: implications for therapy. Cardiovasc Pathol. 2019;43:107139. https://doi.org/10.1016/j.carpath.2019.06.003

7. Shi J, Lv Y, Yu L, Zhang B, Zhang X, Fan C, et al. Interest of a new biodegradable stent coated with paclitaxel on anastomotic wound healing after biliary reconstruction. Eur J Gastroenterol Hepatol. 2013;25(12):1415-23. https://doi.org/10.1097/MEG.0b013e328361eb51

8. Sirica AE. Bile duct epithelial cell culture. Methods Mol Biol. 2002;188:37-52. https://doi.org/10.1385/1-59259-185-x:37

9. Yu Y, Feng XH. TGF-β signaling in cell fate control and cancer. Curr Opin Cell Biol. 2019;61:56-63. https://doi.org/10.1016/j.cceb.2019.07.007

10. Lessard SJ, MacDonald TL, Pathak P, Han MS, Coffey VG, Edge J, et al. JNK regulates muscle remodeling via myostatin/SMAD inhibition. Nat Commun. 2018;9(1):3030. https://doi.org/10.1038/s41467-018-05439-3

11. Shapira KE, Ehrlich M, Henis YI. Cholesterol depletion enhances TGF-β Smad signaling by increasing c-Jun expression through a PKR-dependent mechanism. Mol Biol Cell. 2018;29(20):2494-507. https://doi.org/10.1091/mbc.E18-03-0175

12. Matsuoka K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res. 2012;347(1):225-43. https://doi.org/10.1007/s00441-011-1178-6

13. Yoshida K, Matsuoka K, Murata M, Yamaguchi T, Suwa K, Okazaki K. Clinico-pathological importance of TGF-β/Smad signaling during human hepatic fibrocarnogenesis. Cancers (Basel). 2018;10(6):183. https://doi.org/10.3390/cancers10060183

14. Abe H, Takeda N, Isagawa T, Sembé H, Nishimura S, Morioka MS, et al. Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M. Nat Commun. 2019;10(1):2824. https://doi.org/10.1038/s41467-019-10859-w

15. Mojsilovic S, Totic M, Mojsilovic S, Zivanovic M, Bjelic S, Srdic Rajic T, et al. Paclitaxel inhibits transforming growth factor-β, increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration. J BUON. 2020;25(2):1257-65. PMID: 32521934

16. Son SS, Kang JS, Lee EY. Paclitaxel ameliorates palmitate-induced injury in mouse podocytes. Med Sci Monit Basic Res. 2020;26:e928265. https://doi.org/10.12659/MSMBR.928265

17. Lyu SC, Wang J, Zhou L, Zhu JQ, Pan F, Jiang T, et al. Mechanism of scar formation following Roux-en-Y cholecdochojenustomy in a novel rat model of obstructive jaundice. Ann Transl Med. 2021;9(6):456. https://doi.org/10.21037/atm-20-5135